As the COVID-19 pandemic laid bare, mental health is one of the largest underserved areas in the medical community. With few solutions in sight, there is a growing body of evidence that suggests that psychedelic-assisted therapy could provide a breakthrough in treating countless mental health ailments, such as depression, substance abuse disorders, and PTSD.

NEW YORK CITY, May 18, 2022 /PRNewswire/ — As world leaders come together to discuss the global economy at the World Economic Forum’s annual gathering, the world’s most prominent psychedelic industry leaders, drug development experts, clinicians, nonprofit organizations, advocates, and influencers will gather separately in Davos at the inaugural Medical Psychedelic Series to help shape the future of mental health.

“This is a one-of-a-kind opportunity for the medical psychedelics ecosystem to share the breakthroughs in psychedelic therapeutics for the first time with world leaders,” says Marik Hazan, CEO of Energia Holdings Incorporated.

The clinical evidence for psychedelic assisted therapy is accumulating. A recent publication in the prominent peer-reviewed journal Nature, shows that 67% of patients no longer qualified for a PTSD diagnosis a year after treatment with MDMA (or “ecstasy”). Promising results have also been published for treatment of depression and smoking cessation with psilocybin (the psychoactive compound in “magic mushrooms”).

“Clinical research findings published in recent years suggest that psychoactive compounds could be very effective for treating mental health ailments, though we still have a lot more research to conduct if we are to roll out these therapies in the safest possible way”, says Maria Velkova, managing partner of Tabula Rasa Ventures, an accelerator that works with psychedelics startups.

The inaugural week-long series will take place from May 21-26, 2022, at the Medical Psychedelics House of Davos located at Platzhirsch Club Davos, Promenade 63, 7270 Davos, Switzerland. The full program can be found here.

Hosted by Energia Holdings Incorporated, the series includes educational talks and panels featuring some of the best-known figures in the psychedelic space, including psychedelic researcher David Nichols, PhD; Endowed Professor & Vice Chair of Psychiatry, Icahn School of Medicine at Mount SinaiRachel Yehuda, PhD and world-renowned founder of the Beckley Foundation Amanda Fielding. Acclaimed author and psychedelic medicine advocate Deepak Chopra and TV personality and advocate Jason Silva will also be speaking during the weeklong series. Over 40 key opinion leaders from all over the world will be participating in the event.

The majority of conversations at the Medical Psychedelics House of Davos will focus on regulatory approval for these compounds, their therapeutic potential, policy, safety and efficacy, biocultural preservation, drug development pipelines, and patient access.

“We want to spark conversations about the high unmet need in mental health, the future of regulatory approval for psychedelic-assisted therapy, provide a platform for establishing meaningful relationships and partnerships, and build trust with the global community,” says Velkova. “We know that when the general public hears ‘psychedelics’ they first think about ‘shamans’ and ‘hippies’, but what we hope to show over our weeklong series is the evidence-based legitimacy behind psychedelics when used for treatment in the clinical setting”, added Hazan.

At Davos 2022, This Medical Psychedelics Series Will Be the Global Platform for Where Select Attendees Will:

• Learn from leading experts in the medical psychedelics industry who are setting the narrative for both mental health and psychedelic therapeutics on the global stage in front of world leaders.

• Experience sessions curated to engage all six senses and give an unforgettable heart-opening, mind-stimulating, experience of human connection through sound meditation, breathwork, and conscious leadership workshops.

• Connect with psychedelic entrepreneurs, researchers, policy makers, and nonprofit leaders and some of the world’s most innovative psychedelic organizations like the Multidisciplinary Association for Psychedelic Studies (MAPS), Maya Health, Compass Pathways, Imperial College London, and many others.

We invite you to join us on our mission to shape the principles, policies, and partnerships needed to support the medical psychedelics movement and transform the mental health crisis.